COVID-19-Related Hypercoagulability as a Long-term Complication in SARS-CoV-2: Lessons from SARS and MERS

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) leads to a various clinical and laboratory findings in affected patients. Similar to the previous outbreak, patients with SARS-CoV-2 showed elevated levels of D-dimer, thrombocytopenia, and prolonged prothrombin time and the activated partial thromboplastin time. Meanwhile two lethal coagulation disorders of disseminated intravascular coagulation and pulmonary embolism have already been reported in patients with SARS-CoV-2. Although further cohort studies are needed to document long-term complications, considering the similar pathogenicity of SARS-CoV and SARS-CoV-2, the same chronic cardiovascular impairments could be expected.